Eureka Therapeutics

Executive Summary

Eureka Therapeutics is a clinical-stage biopharmaceutical company pioneering T cell-based therapies for solid tumors. Its proprietary ARTEMIS™ T cell platform is designed to uniquely target intracellular cancer antigens presented by MHC molecules, enabling potent and precise T cell activation while reducing off-tumor toxicity. The company's lead candidate, ET-01 (an ARTEMIS-based TCR-T therapy targeting a solid tumor antigen), is currently in Phase 1/2 clinical trials, with early efficacy signals and a manageable safety profile observed in initial cohorts. Eureka's robust discovery engine also includes bispecific antibodies and novel cytokine technologies, positioning the company to address diverse unmet needs in oncology. Despite being private, Eureka has garnered significant interest due to its innovative approach to overcoming the immunosuppressive tumor microenvironment, a key challenge in solid tumor immunotherapy. With a strong intellectual property portfolio and experienced management team, Eureka Therapeutics represents a promising player in the next wave of T cell therapies.

Upcoming Catalysts (preview)

• Q2 2026Phase 1/2 initial efficacy data for ET-01 in solid tumors60% success
• Q4 2026IND filing for next-generation ARTEMIS candidate targeting novel antigen70% success
• Q3 2026Potential corporate partnership for platform technology (e.g., bispecific antibodies)50% success